We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 21st:
Mallinckrodt plc : This developer and manufacturer of specialty pharmaceutical products and therapies has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 13.7% over the last 60 days.
Mallinckrodt public limited company Price and Consensus
Danaos Corporation (DAC - Free Report) : This owner and operator of containerships in Australia, Asia, Europe, and the United States has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 1.6% over the last 60 days.
Elevate Credit, Inc. : This provider of online credit solutions to non-prime consumers in the United States and the United Kingdom has Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 25% over the last 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Top Ranked Value Stocks to Buy for December 21st
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 21st:
Mallinckrodt plc : This developer and manufacturer of specialty pharmaceutical products and therapies has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 13.7% over the last 60 days.
Mallinckrodt public limited company Price and Consensus
Mallinckrodt public limited company price-consensus-chart | Mallinckrodt public limited company Quote
Mallinckrodt has a price-to-earnings ratio (P/E) of 0.06 compared with 0.20 for the industry. The company possesses a Value Score of A.
Mallinckrodt public limited company PE Ratio (TTM)
Mallinckrodt public limited company pe-ratio-ttm | Mallinckrodt public limited company Quote
Danaos Corporation (DAC - Free Report) : This owner and operator of containerships in Australia, Asia, Europe, and the United States has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 1.6% over the last 60 days.
Danaos Corporation Price and Consensus
Danaos Corporation price-consensus-chart | Danaos Corporation Quote
Danaos has a price-to-earnings ratio (P/E) of 2.85 compared with 9.70 for the industry. The company possesses a Value Score of A.
Danaos Corporation PE Ratio (TTM)
Danaos Corporation pe-ratio-ttm | Danaos Corporation Quote
Elevate Credit, Inc. : This provider of online credit solutions to non-prime consumers in the United States and the United Kingdom has Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 25% over the last 60 days.
Elevate Credit, Inc. Price and Consensus
Elevate Credit, Inc. price-consensus-chart | Elevate Credit, Inc. Quote
Elevate Credit has a price-to-earnings ratio (P/E) of 3.04 compared with 12.90 for the industry. The company possesses a Value Score of A.
Elevate Credit, Inc. PE Ratio (TTM)
Elevate Credit, Inc. pe-ratio-ttm | Elevate Credit, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Value score and how it is calculated here.
Find more top income stocks with some of our great premium screens.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>